93 related articles for article (PubMed ID: 27564312)
1. Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.
Engelstein R; Merims S; Eisenberg G; Cohen J; Frank S; Hamburger T; Frankenburg S; Ron I; Isacson R; Grenader T; Steinberg H; Cohen CJ; Peretz T; Lotem M
J Immunother; 2016 Oct; 39(8):321-8. PubMed ID: 27564312
[TBL] [Abstract][Full Text] [Related]
2. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
3. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.
Sluijter BJ; van den Hout MF; Stam AG; Lougheed SM; Suhoski MM; van den Eertwegh AJ; van den Tol MP; van Leeuwen PA; Meijer S; Scheper RJ; June CH; de Gruijl TD; Santegoets SJ
Clin Immunol; 2010 Nov; 137(2):221-33. PubMed ID: 20708974
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
5. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
[TBL] [Abstract][Full Text] [Related]
6. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
7. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
8. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.
Friedman KM; Devillier LE; Feldman SA; Rosenberg SA; Dudley ME
J Immunother; 2011; 34(9):651-61. PubMed ID: 21989413
[TBL] [Abstract][Full Text] [Related]
9. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
[TBL] [Abstract][Full Text] [Related]
10. Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
Kim S; Sohn HJ; Lee HJ; Sohn DH; Hyun SJ; Cho HI; Kim TG
J Immunother; 2017 Apr; 40(3):83-93. PubMed ID: 28099196
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
13. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.
Aspord C; Leccia MT; Salameire D; Laurin D; Chaperot L; Charles J; Plumas J
J Invest Dermatol; 2012 Oct; 132(10):2395-2406. PubMed ID: 22696054
[TBL] [Abstract][Full Text] [Related]
14. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
15. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
16. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
17. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
[TBL] [Abstract][Full Text] [Related]
18. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
Linette GP; Zhang D; Hodi FS; Jonasch EP; Longerich S; Stowell CP; Webb IJ; Daley H; Soiffer RJ; Cheung AM; Eapen SG; Fee SV; Rubin KM; Sober AJ; Haluska FG
Clin Cancer Res; 2005 Nov; 11(21):7692-9. PubMed ID: 16278389
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.
Daniel-Meshulam I; Horovitz-Fried M; Cohen CJ
Int J Cancer; 2013 Dec; 133(12):2903-13. PubMed ID: 23754772
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effect of 4-1BBL combined with Hsp70-tumor antigen peptides on pulmonary metastasis of melanoma in mice].
Qiu H; Zhang GM; Zhang H; Yuan Y; Li D; Feng ZH
Ai Zheng; 2005 Jul; 24(7):781-6. PubMed ID: 16004800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]